Geron Corp (NAS:GERN)
$ 4.54 0.06 (1.34%) Market Cap: 2.74 Bil Enterprise Value: 2.46 Bil PE Ratio: 0 PB Ratio: 8.90 GF Score: 35/100

Q2 2021 Geron Corp Earnings Call Transcript

Aug 16, 2021 / 08:30PM GMT
Release Date Price: $1.2 (-1.64%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Q2 2021 Geron Earnings Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Ms. Olivia Bloom. Please go ahead.

Olivia Kyusuk Bloom
Geron Corporation - Executive VP of Finance, CFO & Treasurer

All right. Thank you very much, Grace, and good afternoon, everyone. Welcome to this conference call to discuss updates on our ongoing imetelstat Phase III clinical trials as well as second quarter financial results.

I am joined today by Dr. John Scarlett, Geron's Chairman and Chief Executive Officer; Dr. Aleksandra Rizo, Geron's Executive Vice President and Chief Medical Officer; and Anil Kapur, Geron's Executive Vice President of Corporate Strategy and Chief Commercial Officer.

After the market closed today, we announced updates on our IMerge Phase III clinical trial and financial results for our second quarter via press release, which is available on our website. In

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot